K E Y W W W.C M O L E A D E R S H I PA W A R D S .C O M
2016
CMO
LEADERSHIP
AWARDS
WINNERS
Company
Profiles
LIFESCIENCELEADER.COM THE CMO LEADERSHIP AWARDS 2016
58
CAPABILITIES COMPATIBILITY EXPERTISE QUALITY RELIABILITY
INDIVIDUAL ATTRIBUTE AWARDS: reputation,
strength of science
INDIVIDUAL ATTRIBUTE AWARDS: accessible
senior management, cultural fit, innovation,
on-time, reputation, right first time, state-of-the-art,
strength of science
INDIVIDUAL ATTRIBUTE AWARDS: accessible
senior management, cultural fit, innovation,
on-time, reputation, right first time, state-of-the-art,
strength of science
SERVICES & CAPABILITIES: cytotoxic & high
potency compounds, peptides, proteins
"With these awards, Lonza is being recognized
for our quality initiatives, reliability, expertise,
and compatibility. In 2015 our efforts resulted in
successful regulatory inspections and customer
audits at our cGMP sites, supporting our rank as
a reliable partner. We strive continuously to reach
the next level of excellence in commercial and
innovation activities to help our customers' value
chains. We are a more customer-focused and
market-driven organization and believe our high
rankings reflect this change."
SERVICES & CAPABILITIES: ADC payloads,
chromatography, CMO services, cytotoxic &
high potency compounds, generics, hazardous
chemistry, mAbs, peptides, proteins, purification,
vaccines, viral vectors
"Sincere thanks to all the customers and partners
who voted for us in these 15 categories. Our
commitment and efforts in delivering first-class
service to our customers have been recognized.
For three years, our new strategy has focused
on day-to-day activities to meet the needs of our
partners and customers.
These awards support our teams in delivering
the projects announced this year: a state-of-the-art
ADC conjugation facility and the expansion of our
U.S. laboratory."
SERVICES & CAPABILITIES: aseptic fill/finish,
cell culture, cell & virus banking, cytotoxic & high
potency compounds, fermentation, formulation,
injectables, liquids, non-sterile, parenterals
(small volume), peptides, process development,
purification, proteins, solutions & suspensions,
sterile, vaccines
DRUG TYPE:
Biopharmaceuticals
DRUG TYPE:
Pharmaceuticals, Biopharmaceuticals
DRUG LIFE CYCLE STAGES:
Research & Development: Discovery, Preclinical,
Clinical (Phase 1, Phase 2, Phase 3)
Drug Substance Production: Primary Process
Development, Drug Substance Production
DRUG LIFE CYCLE STAGES:
Research & Development: Clinical (Phase 1,
Phase 2, Phase 3)
Drug Substance Production: Primary Process
Development, Drug Substance Production
DRUG LIFE CYCLE STAGES:
Research & Development: Discovery, Preclinical,
Clinical (Phase 1)
Drug Substance Production: Primary Process
Development, Drug Substance Production
Formulated Drug Production: Dosage Form
Development, Dosage Form Production,
Packaging
DRUG TYPE:
Biopharmaceuticals
RICHARD RIDINGER
CEO
THIERRY VAN
NIEUWENHOVE
President, Synthesis Business Unit
CATEGORIES WON CATEGORIES WON CATEGORIES WON
Paragon Bioservices, Inc.
Baltimore, MD
www.paragonbioservices.com
+1 410 975 4050
Philip Wills
pwills@paragonbioservices.com
Key locations: Baltimore, MD
NOVASEP
Lyon, France
www.novasep.com
+33 437 282 030
Andrew Brennan
andrew.brennan@novasep.com
Key locations: Le Mans, France; Mourenx, France;
Pompey, France; Leverkusen, Germany; Seneffe,
Belgium; Boothwyn, PA, U.S.A.
Lonza
Basel, Switzerland
www.lonza.com
+41 61 316 81 11
Sean Diver
sean.diver@lonza.com
Key locations: Houston, TX, Portsmouth, NH,
Walkersville, MD, U.S.A.; Porriño, Spain;
Slough, UK
PETER BUZY
President & CFO
"Responsibility to our clients, a passion for
science, and our collective need to contribute
to better public health — that's what keeps us
motivated and excited about the work that we
perform. We are driven by our commitment to
provide exceptional quality, scientific excellence,
and superior customer service. We bring 25
years of experience working with biologics to
every client project — from research and process
development services to GMP manufacturing for
Phase 1-2 clinical trials."